SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin. 2001; 51: 1537.
  • 2
    Byar DP. Review of the veterans administration studies of cancer of the prostate and new results concerning treatment of Stage I and II tumors. In: Pavone-MalacusoM, SmithPH, Eds myrF, editors. Bladder tumors and other topics in urological oncology. New York: Plenum Press, 1980: 471492.
  • 3
    Crawford ED, Eisenberger MA, McLeod DC, et al. A controlled randomized trial of leuprolide with and without flutamide in prostatic cancer. N Engl J Med. 1989; 321: 419424.
  • 4
    Denis L, Whetan P, Carneiro D, et al. Goserelin acetate and flutamide versus bilateral orchiectomy: a Phase III EORTC study (30853). Urology. 1993; 42: 119130.
  • 5
    Eisenberger MA, O'Dwyer PJ, Friedman MA. Gonadotropin hormone releasing analogues: a new therapeutic approach for prostate cancer. J Clin Oncol. 1986; 4: 414424.
  • 6
    McLeod DC. Hormonal therapy in the treatment of carcinoma of the prostate. Cancer. 1995; 75: 19141919.
  • 7
    Turkes AO, Peeling WB, Griffith H. Treatment of patients with advanced cancer of the prostate: Phase III trial, zoladex against castration: a study of the British prostate group. J Steroid Biochem. 1987; 27: 543549.
  • 8
    Hudes G, Greenburg R, Krigel R. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol. 1992; 10: 17541761.
  • 9
    Hartley-Asp B, Kruse E. Nuclear protein matrix as a target for estramustine-induced cell death. Prostate. 1986; 9: 387395.
  • 10
    Murphy GP, Slack NH, Mittleman A. Use of estramustine phosphate in prostate cancer by the National Prostate Cancer Project and by Roswell Park Memorial Institute. Urology. 1984; 123(Suppl): 5463.
  • 11
    Kreis W, Budman D. Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer. Semin Oncol. 1999; 26 (5 Suppl 17): 34–38.
  • 12
    Hudes GR, Nathan FE, Khater C, et al. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol. 1995; 22(Suppl 12): 4145.
  • 13
    Seidman AD, Scher HI, Petrylak D, et al. Estramustine and vinblastine: use of prostatic specific antigen as a clinical trial endpoint for hormone refractory prostate cancer. J Urol. 1992; 147: 931934.
  • 14
    Pienta KJ, Redman BG, Hussain M, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate. J Clin Oncol. 1994; 12: 20052012.
  • 15
    Smith DC, Esper P, Strawderman M, et al. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol. 1999; 17: 16641671.
  • 16
    Kreis W, Budman DR, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol. 1997; 79: 196202.
  • 17
    Friedland D, Cohen J, Miller R Jr., et al. A Phase II trial of docetaxel (Taxotere) in hormone refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol. 1999;26(Suppl 17): 1923.
  • 18
    Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone refractory prostate cancer: preliminary results. Semin Oncol. 1999; 26(Suppl 17): 1418.
  • 19
    Beer TM, Pierce WC, Lowe A, et al. Phase II study of weekly docetaxel (Taxotere) in hormone refractory metastatic prostate cancer (HRPC) [abstract 1368]. Proc Am Soc Clin Oncol. 2000; 19: 348a.
  • 20
    Kreis W, Budman DR, Fetten J, et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate cancer. Ann Oncol. 1999; 10: 3338.
  • 21
    Petrylak DP, MacArthur RB, O'Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 1999; 17: 958967.
  • 22
    Savarese D, Taplin M, Halabi S, et al. A Phase II study of docetaxel (Taxotere), estramustine, and low dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of Cancer and Leukemia Group B Trial 9780. Semin Oncol. 1999; 26(Suppl 17): 3944.
  • 23
    Petrylak DP, Macarthur R, O'Connor J, et al. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin Oncol. 1999; 26(Suppl 17): 2833.
  • 24
    Speicher LA, Barone L, Tew KD. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res. 1992; 52: 44334440.
  • 25
    Speicher LA, Barone LR, Chapman AE, et al. P-gycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J Natl Cancer Inst. 1994; 86: 688694.
  • 26
    Bubly GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the PSA Working Group. J Clin Oncol. 1999; 17: 17.
  • 27
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J. 1958; 53: 457480.
  • 28
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22: 719748.
  • 29
    SAS Institute. SAS user's guide: statistics, version 5 edition. Cary: SAS Institute, 1985.
  • 30
    Statistics and Epidemiology Research Corporation (SERC). EGRET user's manual. Seattle: SERC, 1988.
  • 31
    Petrylak DP, Shelton GB, England-Owen C, et al. Response and preliminary survival results of a Phase II study of docetaxel (D) + estramustine (E) in patients (Pts) with androgen-independent prostate cancer (AIPCA) [abstract 1312]. Proc Am Soc Clin Oncol. 2000; 19: 334a.
  • 32
    Hudes GR, Nathan FE, Khater C, et al. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol. 1995; 22(Suppl 12): 4145.
  • 33
    Smith DC, Esper P, Strawderman M, et al. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone refractory prostate cancer. J Clin Oncol. 1999; 17: 16641667.
  • 34
    Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96 hour paclitaxel plus oral estramustine phosphate in metastatic hormone refractory prostate cancer. J Clin Oncol. 1997; 15: 31563163.
  • 35
    Berry W, Gregurich M, Dakhil S, et al. Phase II randomized trial of weekly paclitaxel (Taxol®) with or without estramustine phosphate in patients with symptomatic, hormone refractory, metastatic carcinoma of the prostate (HRMCP) [abstract 696]. Proc Am Soc Clin Oncol. 2001; 20: 175a.